Pharmacology, Toxicology and Pharmaceutical Science
4,4' Isopropylidenediphenol
16%
Adverse Event
29%
Amyotrophic Lateral Sclerosis
33%
Aquaporin 4 Antibody
33%
Atrial Fibrillation
16%
Brain Hemorrhage
33%
Calcitonin Gene Related Peptide
33%
Cholinergic Receptor Antibody
39%
Clinical Trial
45%
Cohort Study
18%
Coronavirinae
16%
Disease
88%
Disease Exacerbation
19%
Drug Discovery
21%
Drug Induced Headache
16%
Eculizumab
33%
Fremanezumab
34%
Galcanezumab
26%
Headache
38%
Immune Checkpoint Inhibitor
16%
Immunosuppressive Agent
17%
Infection
25%
Lasmiditan
16%
Migraine
100%
Monoclonal Antibody
18%
Multiple Sclerosis
83%
Muscle Weakness
16%
Myasthenia gravis
67%
Myelin
16%
Myelooptic Neuropathy
33%
Myositis
33%
Ofatumumab
16%
Olcegepant
22%
Onset Age
18%
Parkinson's Disease
50%
Placebo
38%
Postmarketing Surveillance
16%
Prospective Cohort Study
16%
Ravulizumab
33%
Recurrent Disease
16%
Retrospective Study
19%
Ropinirole
78%
Satralizumab
16%
Siponimod
16%
Symptom
62%
Tacrolimus
18%
Thymoma
20%
Tolerability
32%
Yokukansan
16%
Zilucoplan
16%
Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Alternative Interventions
33%
Anti-striational Antibodies
33%
Cell-based
20%
Central Nervous System
16%
Cerebral Blood Flow
25%
Clinical Characteristics
20%
Committee Member
16%
Early Intervention
16%
Enteric Glial Cells
16%
Experimental Ischemia
16%
Favorable Outcome
28%
Fc Receptor
35%
Galcanezumab
16%
Gene-deficient Mice
19%
Hormone-like Effects
16%
IgLON5
16%
Immunodeficiency
16%
Immunoglobulin Fc
20%
Ischemic Stroke
19%
Japan
54%
Japanese Society of Neurology
33%
Male Mice
16%
Migraine
20%
Moderate to Severe
16%
Multiple Sclerosis Lesions
25%
Multiple Sclerosis Treatment
39%
Myasthenia Gravis
57%
Myelin Basic Protein
18%
Myocarditis
25%
Myositis
24%
Nationwide Epidemiological Survey
16%
Neurological Diseases
33%
Neurology
50%
Neuromyelitis Optica Spectrum Disorder (NMOSD)
33%
Oligodendrocyte Precursor Cell Differentiation
31%
Oligodendrocyte Precursor Cells
34%
Placebo
20%
Postdrome
16%
Radial Fiber
16%
Research Education
16%
Retinal Migraine
16%
Ropinirole Hydrochloride
33%
Satralizumab
33%
Spreading Depolarization
33%
Systemic Aging
16%
Thymoma
22%
Thymoma-associated Myasthenia Gravis
20%
Tolerability
20%
Traditional Japanese Medicine
16%
Medicine and Dentistry
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Alzheimer's Disease
20%
Amyloid
16%
Angioimmunoblastic T-Cell Lymphoma
16%
Apoplexy
37%
Aquaporin 4 Antibody
20%
Atrial Fibrillation
33%
Blood Clot Lysis
18%
Brain Infarction
18%
Brain Ischemia
59%
Capillary
33%
Cerebral Cortex
16%
Cerebral Hemorrhage
54%
Cholinergic Receptor Antibody
19%
Cognitive Defect
16%
Cohort Analysis
18%
COVID-19
35%
Direct Oral Anticoagulant
16%
Disease
23%
Disease Modifying Therapy
18%
Early Intervention
16%
Erythrocyte
18%
Fremanezumab
20%
Galcanezumab
16%
Headache
52%
Immune Checkpoint Inhibitor
16%
Internal Carotid Artery
16%
Mechanical Thrombectomy
20%
Medication Overuse Headache
16%
Mediobasal Hypothalamus
16%
Migraine
53%
Mild Cognitive Impairment
20%
Multiple Sclerosis
50%
Myasthenia gravis
16%
Neuroinflammation
16%
Neurologic Disease
37%
Neurology
44%
Neuromyelitis Optica
33%
Neurotropin
16%
Parkinson's Disease
33%
Ravulizumab
33%
Retinal Migraine
16%
Retrospective Study
16%
Satralizumab
16%
Symptom
23%
Thymoma
16%
Thyroiditis
16%
Transverse Myelitis
16%
Urology
16%
Yokukansan
16%
